Background: Adenocarcinoma of the prostate can present as metastatic carcinoma with no known primary. Prostatic origin can be confirmed in most of these cases by immunohistochemistry for prostate-specific antigen (PSA) and prostate-specific acid phosphatase. In a small subset of high-grade prostate carcinomas, both markers are negative and therefore are not helpful for confirming prostatic origin. Recently, novel marker proteins that are preferentially expressed in prostate tissue were identified. One such marker is P501S or prostein, a 553-amino acid protein that is localized to the Golgi complex. It is expressed in both benign and neoplastic prostate tissues, but not in any other normal or malignant tissue examined to date. Owing to its apparent specificity, prostein may be a good marker to demonstrate prostatic origin in metastatic prostate cancer.
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Design: Five-micron sections of a tissue microarray were subjected to immunohistochemistry with a monoclonal mouse anti-P501S (clone 10E3, Dako, Carpintera, CA) antibody and a monoclonal mouse anti-PSA (clone ER-PR8, Dako, Carpintera, CA) antibody. The tissue microarray contains 78 cases of metastatic prostatic adenocarcinoma, 20 cases of primary prostatic adenocarcinoma, and 20 cases of benign prostate tissue from the peripheral zone as well as samples of benign brain, pancreas, kidney, thyroid, testis, skeletal muscle, and fibroconnective tissue.
Results: Similar staining (intensity and extent) was identified for both markers in the majority of metastatic tumors (11 distant sites, 42 pelvic lymph nodes), in all 20 primary tumors and in all benign prostate and nonprostate tissues. The P501S stain had perinuclear cytoplasmic (Golgi) distribution even in poorly differentiated tumors and metastases. Two distant metastases were negative for PSA but retained focal weak positivity for P501S. Two other distant metastases were weakly PSA positive, but strongly P501S positive. Metastases in the pelvic lymph nodes were positive for both markers in 53 cases and 1 lymph node metastasis was strongly PSA positive but P501S negative. In summary, 67 of the 69 cases (97%) of metastatic prostate carcinomas were PSA positive, whereas 68 of the 69 cases showed at least focal weak reactivity for P501S (99%). None of the tumors were negative for both markers.
Conclusions:
Immunohistochemistry for P501S is a sensitive and highly specific marker for identifying prostate tissue. The large majority of metastatic prostatic adenocarcinomas are P501S positive (99%). A small subset of metastatic prostatic adenocarcinoma shows significant differences in staining intensity and extent for PSA and P501S and, therefore, combined use of these markers may result in increased sensitivity for detecting prostatic origin. P rostate cancer is the most common cancer in men and is the second leading cause of cancer death in men. 8 It is typically diagnosed on needle core biopsies in patients with elevated serum levels of prostate-specific antigen (PSA) and less frequently as a result of an abnormal digital rectal examination. A minority of patients, however, present with metastatic disease of unknown origin, whereas others require confirmation of prostatic origin of poorly differentiated tumors involving the prostate and adjacent organs. This is most often achieved by immunohistochemistry for PSA, which is a sensitive and specific marker of prostatic differentiation and is positive in the large majority of prostatic adenocarcinomas. 3, 6, 10, 11, 13 A small subset of prostate cancers that are usually poorly differentiated show only weak or no expression of PSA.
2,4,13 PSA expression has also been described in nonprostatic neoplasms, including adenocarcinoma of the urinary bladder, 5 colon, 14 malignant melanoma, 1 and salivary gland neoplasms, 7, 12 and therefore, there is a need for additional more specific and sensitive markers.
Prostein is a 553-amino acid protein identified by cDNA library subtraction and subsequent high-throughput microarray screening of prostate cancer. 15 Currently, its function is not known, but it seems to be selectively expressed in prostatic epithelium, both benign and malignant. 9, 15 Prostein expression also seems to be unrelated to Gleason grade. 15 The protein is localized to the cytoplasm, and immunohistochemistry shows a prominent dotlike Golgi complex staining. 9 In a recent immunohistochemical study using a murine monoclonal antiprostein antibody, all 65 cases of normal and neoplastic prostate tissue were positive, and all 4635 samples of different nonprostate tissues and associated neoplasms were negative. 9 On the basis of its apparent specificity, prostein may be a useful marker to confirm prostatic origin of poorly differentiated prostatic tumors and in metastatic carcinomas with no known primary. To evaluate the applicability of prostein immunohistochemistry, we used a tissue microarray (TMA) containing samples of benign prostate tissue, primary and metastatic adenocarcinoma of the prostate, and a limited number of benign nonprostate tissues. Table 1 . Preoperative serum PSA levels were available for 32 patients with metastases and ranged from 3.7 to 8796 ng/mL (median 11.25 ng/mL). We do not routinely grade metastases and, therefore, no Gleason grade was assigned for the metastases except in 6 cases for which the primary Gleason grade was not known.
MATERIALS AND METHODS

Materials
Immunohistochemistry
Immunohistochemistry was performed on 5-mm sections of the TMA using a monoclonal mouse anti-P501S antibody (clone 10E3, Dako, Carpintera, CA) and a polyclonal mouse anti-PSA antibody (prediluted, Ventana Medical Systems, Inc, Tucson, AZ). The P501S stain required antigen retrieval in sodium citrate buffer (pH 6.0, 20 min at 90 to 1001C, Black and Decker Flavor Scenter Steamer plus) and blocking (Signet blocker, Signet Laboratories, Inc, Dedham, MA). The primary P501S antibody (1:100) was incubated for 30 minutes at room temperature followed by H 2 O 2 for 7 minutes. Detection was performed using Envision+ (K4061, Dako, Carpentaria, CA). The PSA stain was performed on a Ventana Benchmark XT autostainer with no antigen retrieval. The prediluted antibody was incubated for 16 minutes at 371C and detection was performed using I-VIEW DAB (760-091, Ventana Medical Systems, Inc, Tucson, AZ).
Scoring
The staining intensity was recorded as none, weak, or moderate to strong. Extent of staining was noted as none, focally positive (<10% of cells), and positive (>10% of cells).
RESULTS
All benign nonprostate tissues were negative for both markers, whereas strong and diffuse staining for both PSA and prostein was noted in all 20 cases of benign prostate tissues and in all 20 cases of primary adenocarcinoma of the prostate (Fig. 1) . The majority of primary carcinomas showed strong, diffuse staining for both markers, except for 1 case with a Gleason score of 3+3 = 6 that showed weak staining for both PSA and prostein. In all cases, including poorly differentiated tumors and metastases, P501S (prostein) exhibited perinuclear cytoplasmic staining consistent with a Golgi distribution.
Eight of the 62 cases with pelvic lymph node metastases were excluded because of lack of tissue or absence of carcinoma in the sample. Forty-two cases showed concordant moderate or strong staining for both PSA and prostein. Seven cases had stronger PSA positivity, and 4 cases had stronger prostein positivity. Of the 4 cases with stronger prostein staining, 1 case showed high-grade features with strong prostein positivity but only weak PSA staining (Fig. 2) . One lymph node metastasis was strongly PSA positive but prostein negative (Fig. 2) .
Fifteen cases of distant metastases were available for evaluation because 1 case was excluded owing to loss of tissue. Eleven cases showed similar staining for PSA and prostein. Of the 4 cases with dissimilar staining, 2 were PSA negative with focal weak prostein positivity (Fig. 3) , and 2 were weakly PSA positive but with strong prostein positivity. The results are summarized in the table. Serum PSA levels were available for 32 metastases (26 pelvic lymph nodes and 6 distant metastases) and included 2 cases with discrepant staining for PSA and prostein. Both cases were pelvic lymph node metastases that were strongly PSA positive and either prostein negative (PSA 11.5 ng/mL, Gleason grade 3+4 = 7) or focally prostein positive (PSA 8.5 ng/mL, Gleason grade 3+3 = 6). No correlation between serum PSA levels and Gleason grade was identified.
DISCUSSION
With the development of targeted therapies for the treatment of cancer, discovery and assessment of tumorspecific markers has become central importance. Prostein was identified using a novel strategy for identification of tumor and/or tissue-specific gene expression, and preliminary data suggest that it is preferentially expressed in prostate tissue. 9, 15 Although its function is unknown, the genetic sequence shows closest homology with human AIM-1 protein, a shared melanoma antigen. 15 The gene was mapped to chromosome 1 between bands q32 and q42, a region linked to prostate cancer susceptibility in hereditary cases. 15 Although prostein was only recently identified, extensive testing has been performed to confirm prostate-specific expression. Prostein mRNA expression was demonstrated at 2 to 66.5-fold times higher levels in prostate tissues than in paired normal tissues, and no correlation between prostein mRNA expression and Gleason grade was identified in adenocarcinoma of the prostate. 15 Although 1 breast cancer cell line expressed low levels of prostein, all other nonprostate cancer cell lines showed no expression of prostein. 15 Using a newly developed prostein-specific antibody, positive staining was demonstrated in 111/118 (94%) samples of benign and malignant prostate tissues, and negative staining in 4635 samples of nonprostate tissues that included both benign and malignant tissues. 9 Owing to the apparent high sensitivity and specificity of prostein, our goal was to evaluate the utility of prostein immunohistochemistry for confirming prostatic origin in metastatic tumors. Prostein showed strong, diffuse staining in all benign prostate samples and the majority of primary prostatic carcinomas, which was comparable with PSA staining. One case of primary prostatic carcinoma showed weak staining for prostein, also concordant with the PSA staining pattern. Prostein and PSA showed similar staining characteristics in pelvic lymph node metastases, with only 12/54 (22%) showing stronger staining with either PSA or prostein. Prostein staining was present in 15 of the 15 distant metastases, whereas PSA was only positive in 13 cases, including 2 cases with only weak PSA staining. The latter 2 cases, however, demonstrated strong prostein staining. Only 1 case of metastatic prostatic carcinoma, a pelvic lymph node metastasis, showed absence of prostein staining. Although the number of cases is limited, the results suggest that prostein is both a highly sensitive and specific marker for identifying prostate tissue, whether benign or malignant. In general, prostein performed similarly to PSA, however, prostein was positive in 2 cases of metastatic adenocarcinoma of the prostate that were PSA negative. Prostein also showed no significant background staining and consistently exhibited a perinuclear cytoplasmic staining pattern which was easily interpretable in most cases. Focal weak staining for both markers can be difficult to distinguish from artifacts and, therefore, should be interpreted with caution. Our results demonstrate that a minority of adenocarcinomas of the prostate exhibit different staining intensity for PSA and prostein with some cases only staining for 1 of these markers. Thus immunohistochemistry for prostein and PSA when used together is more accurate for detecting prostatic origin. However, additional cases of metastatic prostate cancers and high-grade primary tumors with Gleason score of 9 and 10 need to be studied to strengthen these findings.
In summary, prostein is a highly sensitive and specific marker of prostatic differentiation and seems to be useful for confirming prostatic origin in metastatic adenocarcinomas of the prostate. The sensitivity can be further increased when immunohistochemistry for prostein is used in combination with immunohistochemistry for PSA, and therefore a panel using both markers is recommended in cases of metastatic carcinoma of unknown origin, where prostatic carcinoma is suspected based on morphology or clinical findings. 
